Cambridge Antibody Technology Group PLC
The Milstein Building
Granta Park
Granta Park
Cambridge
CB1 6GH
United Kingdom
Tel: 44-0-1223-471471
Fax: 44-0-1223-471472
Website: http://www.cambridgeantibody.com/
Email: info@cambridgeantibody.com
36 articles about Cambridge Antibody Technology Group PLC
-
“Humira is an anti-TNF monoclonal antibody that currently treats Crohn's disease, rheumatoid arthritis, ulcerative colitis, hidradenitis suppurativa, psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis and uveitis,” quotes Humira developer AbbVie’s website. Those...
-
Cambridge Antibody Technology: The History Behind UK’s Best Biotech
6/8/2017
-
Cambridge Antibody Technology (CAT) Got The Cream But It Almost Turned Sour
1/5/2016
-
AstraZeneca PLC Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Group PLC Into MedImmune, Inc.
10/29/2007
-
Biotech Firm Cambridge Antibody Technology Group PLC Sheds Jobs as Owner AstraZeneca PLC Submits it to Merger
10/22/2007
-
Dyax Corp. Licenses Antibody Phage Display Libraries to Cambridge Antibody Technology Group PLC
8/2/2007
-
Antitope Announces Composite Protein Research Agreement with Cambridge Antibody Technology Group PLC
4/24/2007
-
Cambridge Antibody Technology Group PLC Licenses Monoclonal Antibody (CAT-213) For Treatment Of Allergy Disorders To iCo Therapeutics Inc.
1/8/2007
-
Cambridge Antibody Technology Group PLC Announces Senior Management Promotions
12/8/2006
-
Cambridge Antibody Technology Group PLC To Expand Operations In Cambridge, UK; To Create Over 200 Jobs
11/7/2006
-
Royalty Pharma AG Announces Agreement Regarding The Purchase Of The Rights To A Pre-Existing Royalty Interest In HUMIRA(R) From AstraZeneca PLC And Cambridge Antibody Technology Group PLC
10/26/2006
-
Cambridge Antibody Technology Group PLC And MSM Protein Technologies Enter Drug Discovery Collaboration In The Field Of Multi-Spanning Membrane Proteins
10/17/2006
-
Cambridge Antibody Technology Group PLC And Debiopharm S.A. Enter Into An Exclusive Agreement To Develop And Market SC-1 For Gastric Carcinomas
10/16/2006
-
The Day In Review: Enzon Pharmaceuticals, Inc. Buys And Sells Drug Progams
7/27/2006
-
Cambridge Antibody Technology Group PLC Announces Acquisition of Oncology Product Candidate From Enzon Pharmaceuticals, Inc.
7/27/2006
-
Molecular Partners AG And Cambridge Antibody Technology Group PLC Sign Cross-Licence Agreement In The Fields Of Repeat Protein Technology And Ribosome Display
7/26/2006
-
Scil Proteins GmbH And Cambridge Antibody Technology Group PLC Sign Cross-Licence Agreement In The Field Of Affilin Technology And Ribosome Display
7/19/2006
-
Cambridge Antibody Technology Group PLC Appoints Hamish Cameron As CEO
6/22/2006
-
Cambridge Antibody Technology Group PLC Announces Interim Results For The Six Months Ended 31 March 2006
5/22/2006
-
The Day In Review: Cambridge Antibody Technology Group PLC Acquisition Keeps Biotech In The Black
5/15/2006